title: [IMPACT OF RONCOLEUKIN ON BALANCE OF CYTOKINS IN COMPLEX TREATMENT OF OBTURATION JAUNDICE OF NONTUMORAL GENESIS].
abstract: The results of surgical treatment of 137 patients, suffering obturation jaundice of non-tumoral etiology, were analyzed. In all the patients the cause of obturation jaundice was choledocholithiasis. Roncoleukin was infused intravenously additionally in a complex of therapy. A degree of hepatic dysfunction was determined, taking into account the cholestasis markers. In 23 patients purulent cholangitis have occurred on background of obturation jaundice. Concentration of cytokins TNF-α, IFN-γ, IL-1, IL-2, IL-4, IL-6, IL-10 in sera were determined, using immunoassay analysis. The cytokins dysbalance severity preoperatively and dynamics of its changes have depended upon the hepatic dysbalance degree and presence of purulent cholangitis; a dysbalance is deeper, when the hepatic dysfunction is higher. Application of pathogenetically substantiated purposeful cytokinotherapy, including roncoleukin, have promoted the cytokins dysbalance elimination and improvement of the patients treatment results.
authors.forename: J N
authors.initials: JN
authors.lastname: Gajiyev
authors.forename: E G
authors.initials: EG
authors.lastname: Tagiyev
authors.forename: N J
authors.initials: NJ
authors.lastname: Gadjiyev
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D002761:Cholangitis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000601:surgery; D042883:Choledocholithiasis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000601:surgery; D002779:Cholestasis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000601:surgery; D003135:Common Bile Duct / Q000187:drug effects / Q000276:immunology / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007275:Injections, Intravenous; D007376:Interleukin-2 / Q000627:therapeutic use*; D041781:Jaundice, Obstructive / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000601:surgery; D008099:Liver / Q000187:drug effects / Q000276:immunology / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D058408:Th1-Th2 Balance / Q000187:drug effects
chemical_list: D015415:Biomarkers; D007155:Immunologic Factors; D007376:Interleukin-2; D011994:Recombinant Proteins